Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable...

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Clinical Pharmacology

Background:

• CYP2C19 gene variants significantly impact patient response to clopidogrel, a standard antiplatelet medication.
• Understanding these genetic influences is crucial for optimizing antiplatelet therapy and preventing thrombotic events.

Purpose of the Study:

• To evaluate the efficacy of increased clopidogrel maintenance doses (up to 300 mg daily) in patients with loss-of-function CYP2C19 genotypes.
• To determine if higher doses can overcome genetic variations affecting clopidogrel response.

Main Methods:

• ELEVATE-TIMI 56 was a multicenter, randomized, double-blind trial involving 333 patients with cardiovascular disease.
• Patients were genotyped for CYP2C19*2 loss-of-function alleles and received varying clopidogrel doses (75-300 mg daily) over four treatment periods.
• Platelet function was assessed using VASP phosphorylation and VerifyNow P2Y(12) assays.

Main Results:

• CYP2C19*2 heterozygotes exhibited higher platelet reactivity on standard 75 mg clopidogrel compared to noncarriers.
• Increasing clopidogrel doses up to 300 mg significantly reduced platelet reactivity in heterozygotes, with 225 mg achieving levels similar to 75 mg in noncarriers.
• A substantial reduction in non-responders was observed with higher doses in heterozygotes (52% to 10%).
• CYP2C19*2 homozygotes showed limited platelet inhibition even with 300 mg clopidogrel.

Conclusions:

• A 225 mg daily dose of clopidogrel effectively normalized platelet reactivity in CYP2C19*2 heterozygotes, similar to the standard dose in noncarriers.
• Higher clopidogrel doses (up to 300 mg) were insufficient to achieve comparable platelet inhibition in CYP2C19*2 homozygotes.
• Dose adjustment based on CYP2C19 genotype may be a strategy to optimize clopidogrel therapy in specific patient populations.